Advantage Alpha Capital Partners’s Charles River Laboratories CRL Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,311	Closed	-$4.25M	–	132
2021 Q3	$4.25M	Sell	10,311 -4,710	-31%	-$1.96M	0.78%	68
2021 Q2	$5.56M	Sell	15,021 -1,894	-11%	-$632K	1.07%	35
2021 Q1	$4.9M	Sell	16,915 -12,982	-43%	-$3.61M	1.03%	43
2020 Q4	$7.47M	Sell	29,897 -4,692	-14%	-$1.12M	1.64%	13
2020 Q3	$7.83M	Sell	34,589 -237	-0.7%	-$49.2K	1.81%	10
2020 Q2	$6.07M	Buy	+34,826	New	+$5.56M	1.42%	23

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advantage Alpha Capital Partners's CRL Position: Q4 2021 in Review

Advantage Alpha Capital Partners sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 10,311 shares — an estimated $4.25M sold.

Advantage Alpha Capital Partners first reported a position in CRL in Q2 2020 and held it in 6 quarters. The position peaked at $7.83M in Q3 2020. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

Advantage Alpha Capital Partners reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
Advantage Alpha Capital Partners sold 10,311 Charles River Laboratories shares in Q4 2021, an estimated $4.25M.
Advantage Alpha Capital Partners first reported a position in Charles River Laboratories in Q2 2020 and held it in 6 quarters.
Advantage Alpha Capital Partners's Charles River Laboratories position peaked at $7.83M in Q3 2020.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.